FDA panel backs Astellas drug for invasive fungal infections

Astellas Pharma Inc's isavuconazonium for the treatment of rare, often fatal invasive fungal infections that can hit patients with blood cancers. the drug will likely see most of its use in immunocompromised patients as well as “patients with poorly controlled diabetes mellitus with or without ketoacidosis, patients undergoing dialysis with iron overload, and patients with trauma or burns.” http://www.reuters.com/article/2015/01/22/astellas-pharma-fda-idUSWEN00EL420150122